A5019763846- Chronic Obstructive Pulmonary Disease (COPD) Research
- Asthma and respiratory diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Pediatric health and respiratory diseases
- Inhalation and Respiratory Drug Delivery
- Allergic Rhinitis and Sensitization
- Systemic Sclerosis and Related Diseases
- Sarcoidosis and Beryllium Toxicity Research
- Medical Imaging and Pathology Studies
- Obstructive Sleep Apnea Research
- Neonatal Respiratory Health Research
- Childhood Cancer Survivors' Quality of Life
- Tracheal and airway disorders
- Sexual function and dysfunction studies
- Palliative Care and End-of-Life Issues
- IL-33, ST2, and ILC Pathways
- Venous Thromboembolism Diagnosis and Management
- COVID-19 Clinical Research Studies
- Airway Management and Intubation Techniques
- Agriculture, Plant Science, Crop Management
- Nosocomial Infections in ICU
- Long-Term Effects of COVID-19
- Fibromyalgia and Chronic Fatigue Syndrome Research
Medical University of Silesia
2015-2024
Górnośląskie Centrum Medyczne
2008-2022
University of Silesia in Katowice
2021
Academy of Fine Arts in Katowice
2021
Central Clinical Hospital
2013-2018
Centralny Szpital Kliniczny
2014-2018
Katowice School of Technology
2007
Lung Institute
2006
Imperial College London
2006
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airway inflammation that greater in patients with advanced disease. We asked whether there a link between the severity of and reduction histone deacetylase (HDAC) activity peripheral lung tissue COPD varying severity. HDAC key molecule repression production proinflammatory cytokines alveolar macrophages.
In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses their role in driving pulmonary inflammation stable COPD is unknown.To investigate immunity pathways bronchial mucosa bronchoalveolar lavage (BAL) patients with different severity control healthy smokers non-smokers.Innate mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ...
Chronic obstructive pulmonary disease (COPD) represents a major health problem in Central and Eastern European (CEE) countries; however, there are no data regarding clinical phenotypes of these patients this region. Participation the Phenotypes COPD Europe (POPE) study was offered to stable with real-life setting. The primary aim assess prevalence according predefined criteria. Secondary aims included analysis differences symptom load, comorbidities pharmacological treatment. 3362 were...
Oral pirfenidone reduces lung function decline and mortality in patients with idiopathic pulmonary fibrosis (IPF). Systemic exposure can have significant side effects, including nausea, rash, photosensitivity, weight loss fatigue. Reduced doses may be suboptimal slowing disease progression.This phase 1b, randomised, open-label, dose-response trial at 25 sites six countries (Australian New Zealand Clinical Trials Registry (ANZCTR) registration number ACTRN12618001838202) assessed safety,...
Psychiatric symptoms of anxiety, depression and cognitive dysfunction often occur in patients suffering from somatic conditions such as asthma chronic obstructive pulmonary disease (COPD) which constitute a major growing public health problem. In the present study we therefore aimed at analyzing depressive well anxiety problems with mild to moderate COPD. 59 participants-17 asthma, 24 COPD 18 healthy controls were enrolled. Depressiveness was assessed beck inventory (BDI); measured...
Abstract Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and of patients IPF observed the multi-national EMPIRE registry. Methods For this prospective cohort, demographics, causes death were analysed. Comorbidities noted by treating physician based on patient’s past medical history or as reported during...
Once a patient has been diagnosed with severe COVID-19 pneumonia, treatment options have limited effectiveness. Opaganib is an oral under investigation being evaluated for of hospitalized patients pneumonia. A randomized, placebo-controlled, double-blind phase 2/3 trial was conducted in 57 sites worldwide from August 2020 to July 2021. Patients received either opaganib (n = 230; 500 mg twice daily) or matching placebo 233) 14 days. The primary outcome the proportion no longer requiring...
This study aimed to examine the distribution of predefined phenotypes, demographic data, clinical outcomes, and treatment patients who were included in Polish cohort Phenotypes COPD Central Eastern Europe (POPE) study.This was a sub-analysis data from POPE study, an international, multicenter, observational cross-sectional survey European countries. The aged >40 years, with confirmed diagnosis COPD, absence exacerbation for at least 4 weeks before inclusion. A total seven centers...
Background: Pulmonary embolism (PE) is the third most common cause of death for cardiovascular diseases in Europe. Quick PE diagnosis therefore crucial prognosis improvement. It critical to have suitable screening tests both exclude as well select patient with highest likelihood occurrence. Currently D-dimer test accepted important tool useful low risk patients. Our goal was assess positive prognostic value. Methods: A retrospective study based on medical record analysis consecutively...
Chronic obstructive pulmonary disease (COPD) constitutes a major health challenge in Central and Eastern European (CEE) countries. However, clinical phenotypes, symptom load, treatment habits of patients with COPD CEE countries remain largely unknown. This paper provides rationale for phenotyping describes the methodology large study CEE.The POPE is an international, multicenter, observational cross-sectional survey CEE. Participation offered to all consecutive outpatients stable 84 centers...
The aim of this study was to assess the impact a single nasal allergen challenge (NAC) on levels eotaxin and IL-8 inflammatory cells in upper lower airways allergic rhinitis (AR) patients. Twenty-four AR patients 12 control subjects entered sequential placebo NAC study, out pollen season. Nasal lavage fluid (NLF) obtained at baseline, 15 minutes, 1, 5, 24 hours postchallenge. Before after placebo/allergen induced sputum performed. NLF were evaluated for total cell count (TCC) differential...